Common Coverage Restrictions for Humira
Insurers often require prior authorization for Humira (adalimumab), meaning doctors must prove medical necessity before coverage kicks in. Step therapy is frequent—patients try cheaper alternatives like methotrexate first. Quantity limits cap doses per month, and some plans exclude certain indications like hidradenitis suppurativa unless others fail.[1]
Why Medicare Limits Humira Coverage
Original Medicare (Parts A/B) doesn't cover outpatient drugs like Humira. Part D plans do, but with restrictions: high copays in the deductible phase (up to $590 in 2024), coverage gaps until catastrophic level, and preferred pharmacy requirements. Inflation Reduction Act caps out-of-pocket at $2,000 starting 2025, but prior auth and step edits persist.[2][3]
How Employer and Marketplace Plans Restrict It
Private plans frequently impose copay accumulators, where manufacturer coupons don't count toward deductibles. High-tier placement leads to 30-50% coinsurance. Some exclude biosimilars initially, forcing brand Humira despite lower costs.[1][4]
Impact of Biosimilars on Coverage
Since 2023 FDA approvals (e.g., Amjevita, Cyltezo), payers push switches to interchangeable biosimilars with 80-85% discounts. Coverage for AbbVie's Humira often requires documented failure on biosimilars first. Citation pricing ties payments to lowest-cost versions.[5]
State Laws Affecting Restrictions
Over 20 states ban copay accumulators for employer plans; others mandate coverage parity for autoimmune drugs. Fail-first laws in states like California limit step therapy waivers.[6]
Patient Assistance Options Around Limits
AbbVie's myAbbVie Assist covers copays up to $14,000/year for eligible patients (income <400-800% FPL). NeedyMeds and RxAssist list copay cards, but accumulators block deductible progress. Biosimilar patient programs offer similar aid.7
[1]: https://www.drugpatentwatch.com/p/tradename/HUMIRA
[2]: https://www.cms.gov/newsroom/fact-sheets/medicare-advantage-2024-medicare-advantage-part-d-star-ratings-and-tuition-assistance-eligible-institutions
[3]: https://www.kff.org/medicare/issue-brief/medicare-part-d-in-2024-a-first-look-at-prescription-drug-plan-availability-premiums-and-cost-sharing/
[4]: https://www.goodrx.com/insurance/health-insurance/copay-accumulator-programs
[5]: https://www.fda.gov/drugs/biosimilars/biosimilar-product-information
[6]: https://www.ncsl.org/health/step-therapy-state-laws